ALGS Aligos Therapeutics Inc.

16.27
-0.03  0%
Previous Close 16.3
Open 15.9
52 Week Low 13.3
52 Week High 37.5099
Market Cap $693,365,428
Shares 42,616,191
Float 19,131,307
Enterprise Value $464,879,912
Volume 96,268
Av. Daily Volume 173,056
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
ALG-010133
Hepatitis B
Phase 1
Phase 1
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.

Drug Pipeline

Drug Stage Notes
ALG-000184
Hepatitis B
Phase 1
Phase 1
Phase 1 safety, pharmacokinetics, and antiviral activity data noted that ALG-000184 administration was associated with similar rapid, substantial reductions in HBV DNA and RNA through the 28-day period, with ≥75% and 100% of evaluable subjects achieving HBV DNA and RNA reductions below the lower limit of quantitation (LLOQ), respectively, noted November 12, 2021.
ALG-055009
Nonalcoholic steatohepatitis (NASH)
Phase 1
Phase 1
Phase 1 trial to commence 4Q 2021.
ALG-020572
Hepatitis B
Phase 1
Phase 1
Phase 1 trial commenced October 11, 2021.

Latest News

  1. COPENHAGEN, Denmark, Nov. 23, 2021 /PRNewswire/ -- Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today the signing of a multi-target drug discovery agreement with Aligos Therapeutics, Inc. (NASDAQ:ALGS). Under the terms of the agreement, Vipergen will apply its high-fidelity DEL technology platforms to identify novel small-molecule compounds that bind to selected Aligos protein targets. Aligos will select hits for development into novel therapeutics for viral and liver diseases. Aligos will retain exclusive rights to globally commercialize any products resulting from the collaboration. Financial details of the agreement were not disclosed.

    "We are delighted to…

    COPENHAGEN, Denmark, Nov. 23, 2021 /PRNewswire/ -- Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies, announced today the signing of a multi-target drug discovery agreement with Aligos Therapeutics, Inc. (NASDAQ:ALGS). Under the terms of the agreement, Vipergen will apply its high-fidelity DEL technology platforms to identify novel small-molecule compounds that bind to selected Aligos protein targets. Aligos will select hits for development into novel therapeutics for viral and liver diseases. Aligos will retain exclusive rights to globally commercialize any products resulting from the collaboration. Financial details of the agreement were not disclosed.

    "We are delighted to collaborate with Aligos' highly experienced team in its mission to develop best-in-class therapies that improve treatment outcomes in chronic hepatitis B, NASH, and coronavirus," said Nils Hansen, PhD, Chief Executive Officer of Vipergen. "We look forward to applying our suite of DEL technologies to discover novel leads that help expand Aligos' portfolio of differentiated drug candidates that target these significant unmet medical needs."

    About Vipergen ApS

    Vipergen is a world-leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies and is the first and only company capable of screening DELs inside a living cell. Vipergen provides its proprietary suite of leading-edge DEL technologies through funded discovery partnerships with leading pharmaceutical and biotechnology companies, including top pharmaceutical companies in the U.S., EU, and Japan. For more details about Vipergen and the YoctoReactor® (yR), Binder Trap Enrichment® (BTE), and Cellular Binder Trap Enrichment® (cBTE) drug discovery technology platforms, please visit www.vipergen.com.

    Contact:

    Mary Moynihan

    M2Friend Biocommunications

    +1 (802) 951-9600

    Cision View original content:https://www.prnewswire.com/news-releases/vipergen-establishes-research-partnership-with-aligos-therapeutics-focused-on-dna-encoded-library-del-based-drug-discovery-for-viral-infections-and-liver-diseases-301430371.html

    SOURCE Vipergen

    View Full Article Hide Full Article
  2. SOUTH SAN FRANCISCO, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos, will present at the Piper Sandler 33rd Annual Virtual Healthcare Conference being held from November 30 - December 2, 2021. The Aligos management team will also participate in virtual investor 1x1 meetings during the conference.

    The webcast of the pre-recorded presentation will be available starting November 22, 2021, 10:00 AM EST on the events section of the Aligos Website or by using the Webcast Registration Link

    SOUTH SAN FRANCISCO, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos, will present at the Piper Sandler 33rd Annual Virtual Healthcare Conference being held from November 30 - December 2, 2021. The Aligos management team will also participate in virtual investor 1x1 meetings during the conference.

    The webcast of the pre-recorded presentation will be available starting November 22, 2021, 10:00 AM EST on the events section of the Aligos Website or by using the Webcast Registration Link. A replay will be available following the presentation for approximately 90-days.

    Please contact your Piper Sandler representative to schedule virtual one-on-one meetings with Aligos during the conference. For more information about the Piper Sandler 33rd Annual Virtual Healthcare Conference, please refer to the Conference Website.

    About Aligos

    Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos' strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.

    Forward-Looking Statement

    This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered "forward-looking statements." Forward-looking statements are typically, but not always, identified by the use of words such as "may," "will," "would," "believe," "intend," "plan," "anticipate," "estimate," "expect," and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including Aligos's clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Aligos's ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of Aligos's capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape and the effects on our business of the worldwide COVID-19 pandemic. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 4, 2021, and its future periodic reports to be filed with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

    Media Contact

    Amy Jobe, Ph.D.

    LifeSci Communications

    +1 315 879 8192

    Investor Contact

    Corey Davis, Ph.D.

    LifeSci Advisors

    +1 212 915 2577



    Primary Logo

    View Full Article Hide Full Article
  3. SOUTH SAN FRANCISCO, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company has appointed Bridget Martell, MA, M.D., to the Company's board of directors.

    "We are pleased to welcome Dr. Martell to our board of directors. Her decades of experience in therapeutics development and leadership in biotechnology will be invaluable to the company as we continue to move our therapeutic candidates, including those for chronic hepatitis B and NASH, through the clinic," said Lawrence Blatt, Ph.D., MBA, Chairman and Chief Executive Officer of Aligos.

    SOUTH SAN FRANCISCO, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company has appointed Bridget Martell, MA, M.D., to the Company's board of directors.

    "We are pleased to welcome Dr. Martell to our board of directors. Her decades of experience in therapeutics development and leadership in biotechnology will be invaluable to the company as we continue to move our therapeutic candidates, including those for chronic hepatitis B and NASH, through the clinic," said Lawrence Blatt, Ph.D., MBA, Chairman and Chief Executive Officer of Aligos.

    Dr. Martell is an accomplished physician and biopharmaceutical executive who currently holds several executive and advisory roles, including as the President and CEO of Artizan Biosciences, a precision medicine microbiome company, a member of the Board of Directors at Achieve Life Sciences, and as a Venture Partner at AlleyCorp's Healthcare Fund.

    Dr. Martell brings extensive scientific acumen to her leadership roles and has been a pivotal leader or major contributor in the success of six marketed products: Kadcyla®, Elelyso®, Intermezzo®, the trastuzumab biosimilar Ogivri®, as well as secondary indications for Pradaxa® and Sutent®. She has held leadership and C-suite executive roles at companies including Kura Oncology, where she led the menin inhibitor program through a period of rapid growth and capital expansion, at Juniper Pharmaceuticals, where she led development of unique combined drug/device technology that was out-licensed for $131M, and at Pfizer, where she had roles of increasing responsibility that included Clinical Team Leader for Sutent® GU solid tumors in the Oncology Business Unit and, ultimately, Biosimilars Medical Head.

    She began her clinical investigation career at Yale with a Career Development Award, where she led a therapeutic cocaine vaccine trial and was a Robert Wood Johnson Clinical Scholar. Dr. Martell was a practicing physician at Yale for 20 years and remains active as an Entrepreneur in Residence at the Office of Cooperative Research. She holds a B.Sc. in Microbiology from Cornell University, an M.A. in Molecular Immunology from Boston University and an M.D. from The Chicago Medical School. Dr. Martell is board certified in Internal and Addiction Medicine.

    Dr. Martell added, "Having been on all sides of therapeutics development, from bench to bedside, I feel that Aligos has developed a portfolio that stands to make a meaningful clinical impact for patients with liver and infectious diseases who thus far haven't been offered the best that already approved therapeutics intended to. I look forward to supporting the Aligos team in strategically navigating their clinical development efforts."

    About Aligos

    Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos' strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.

    Forward-Looking Statement

    This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered "forward-looking statements." Forward-looking statements are typically, but not always, identified by the use of words such as "may," "will," "would," "believe," "intend," "plan," "anticipate," "estimate," "expect," and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including Aligos's clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Aligos's ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of Aligos's capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape and the effects on our business of the worldwide COVID-19 pandemic. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 4, 2021, and its future periodic reports to be filed with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

    Media Contact

    Amy Jobe, Ph.D.

    LifeSci Communications

    +1 315 879 8192

    Investor Contact

    Corey Davis, Ph.D.

    LifeSci Advisors

    +1 212 915 2577



    Primary Logo

    View Full Article Hide Full Article
  4. SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos, will present at the Jefferies London Healthcare Conference and participate in virtual investor 1x1 meetings on the November 18-19, 2021.

    A webcast of the presentation will be available starting November 18, 2021, 8:00 AM GMT / 3:00 AM ET on the events section of the Aligos Website or by clicking the following link: Webcast Registration. A replay will be available following the presentation for 30-days.

    Please contact…

    SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos, will present at the Jefferies London Healthcare Conference and participate in virtual investor 1x1 meetings on the November 18-19, 2021.

    A webcast of the presentation will be available starting November 18, 2021, 8:00 AM GMT / 3:00 AM ET on the events section of the Aligos Website or by clicking the following link: Webcast Registration. A replay will be available following the presentation for 30-days.

    Please contact your Jefferies representative to schedule virtual one-on-one meetings with Aligos during the conference. For more information about the Jefferies London Healthcare Conference, please refer to the Jefferies Conference Website.

    About Aligos

    Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos' strategy is to harness the deep expertise and decades of drug development experience its workforce has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.

    Forward-Looking Statement

    This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered "forward-looking statements." Forward-looking statements are typically, but not always, identified by the use of words such as "may," "will," "would," "believe," "intend," "plan," "anticipate," "estimate," "expect," and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including Aligos's clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Aligos's ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of Aligos's capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape and the effects on our business of the worldwide COVID-19 pandemic. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 4, 2021, and its future periodic reports to be filed with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

    Media Contact

    Amy Jobe, Ph.D.

    LifeSci Communications

    +1 315 879 8192

    Investor Contact

    Corey Davis, Ph.D.

    LifeSci Advisors

    +1 212 915 2577



    Primary Logo

    View Full Article Hide Full Article
  5. Several clinical and nonclinical posters to be presented at the conference

    Aligos' capsid assembly modulator (CAM) candidate, ALG-000184, achieved rapid, substantial reductions in hepatitis B virus DNA and RNA in CHB patients after 28 daily doses

    SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, will present several poster presentations at The Liver Meeting® 2021, hosted by the American Association for the Study of Liver Diseases (AASLD). All of these posters will also be available on the Aligos website at Scientific Presentations & Conferences

    Several clinical and nonclinical posters to be presented at the conference

    Aligos' capsid assembly modulator (CAM) candidate, ALG-000184, achieved rapid, substantial reductions in hepatitis B virus DNA and RNA in CHB patients after 28 daily doses

    SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, will present several poster presentations at The Liver Meeting® 2021, hosted by the American Association for the Study of Liver Diseases (AASLD). All of these posters will also be available on the Aligos website at Scientific Presentations & Conferences as of today and following the conclusion of the conference.

    "As we continue to progress our pipeline with a multifaceted approach to addressing chronic liver diseases, we are pleased to showcase our progress with posters covering our CHB drugs, including STOPS™, CAM, ASO, and siRNA drug candidates, as well as encouraging results from a preclinical study showing additive to synergistic activity when several of these modalities are combined," said Lawrence Blatt, Ph.D., MBA, Chairman and Chief Executive Officer of Aligos. "We believe that combining multiple modalities that reduce hepatitis B virus S-antigen together with drugs that inhibit viral replication will be the key to achieving enhanced functional cure rates in people living with CHB."

    Dr. Blatt continued, "We are especially pleased to present preclinical data further elucidating the molecular mechanism of action for our STOPS molecules as well as clinical data for our CAM drug candidate, ALG-000184, demonstrating good tolerability and significant reductions in HBV DNA and RNA after 28 days of oral dosing. We are also excited to present our THR-β agonist drug candidate, ALG-055009, that has a favorable preclinical pharmacokinetic profile that is supportive of once-daily dosing in humans and appears to have a low risk of drug-drug interactions."

    Chronic Hepatitis B

    S-antigen Transport-inhibiting Oligonucleotide Polymers (STOPS™)

    Title: S-antigen Transport-inhibiting Oligonucleotide Polymers, (STOPS™) Sequester Cellular Proteins to Reduce Hepatitis B Virus S-Antigen Expression and Increase Its Proteasomal Degradation

    Publication Number: 845

    Session Title: Hepatitis B: Therapeutics: New Agents

    Presenter: C. Cheng Kao

    Summary: As part of an in vitro study to elucidate STOPS' mechanism of action in the context of hepatitis B virus (HBV) infection, five host proteins were identified as binding to STOPS. The proteins are known to be involved in RNA processing, translation, and protein folding and degradation, supporting the premise that STOPS molecules likely inhibit HBV infection and hepatitis B virus surface antigen (HBsAg) production by sequestering host proteins needed to express and properly fold the antigen.

    STOPS are Aligos' proprietary single-stranded oligonucleotides that are designed to improve functional cure rates by reducing HBsAg, which is thought to suppress antiviral immune responses in CHB subjects.

    Capsid Assembly Modulator (CAM)



    Title: Safety, Pharmacokinetics (PK), and Antiviral Activity of the Capsid Assembly Modulator (CAM) ALG-000184 in Subjects with Chronic Hepatitis B (CHB)

    Publication Number: 843

    Session Title: Hepatitis B: Therapeutics: New Agents

    Presenter: Ed Gane

    Summary: ALG-000184 is Aligos' class II CAM candidate in development to inhibit HBV infection by interfering with HBV capsid assembly and viral replication by causing the formation of non-infectious empty viral particles.

    As part of the ongoing, three-part, multicenter, double-blind, randomized, placebo-controlled study (NCT04536337), Cohorts 1 and 2 (n=10/cohort; 8 active:2 placebo) of E-antigen (HBeAg)-negative, currently not treated (CNT)/treatment naïve (TN) CHB subjects received 50-mg or 100-mg daily oral doses of ALG-000184 or placebo for 28 days. In both cohorts, ALG-000184 administration was associated with similar rapid, substantial reductions in HBV DNA and RNA through the 28-day period, with ≥75% and 100% of evaluable subjects achieving HBV DNA and RNA reductions below the lower limit of quantitation (LLOQ), respectively.

    Antisense Oligonucleotide (ASO)



    Title: Best-in-Class Antisense Oligonucleotides Against Hepatitis B Virus: Next Generation Bridged Nucleic Acid Chemistries Significantly Increase In Vivo Efficacy and Reduce Hepatotoxicity in Mice

    Publication Number: 820

    Session Title: Hepatitis B: Therapeutics: New Agents

    Presenter: Dinah Misner

    Summary: Aligos' application of next-generation Bridged Nucleic Acid (BNA) chemistries to ASO candidates already using Locked Nucleic Acid (LNA) technology stands to yield a best-in-class ASO candidate in terms of efficacy relative to hepatotoxicity.

    Aligos is advancing ASO drug candidates as part of a combination approach to reducing HBsAg, which suppresses the patient's antiviral immune response in CHB. Historically, hepatotoxicity has been a major side effect of ASOs; however, next-generation BNA chemistries, when used in ASOs that contain LNA components, can reduce hepatotoxicity while maintaining efficacy.

    Title: ALG-020572, a GalNAc-Conjugated Antisense Oligonucleotide, Demonstrates In Vivo Efficacy and Favorable Preclinical Profile for the Treatment of Chronic Hepatitis B

    Publication Number: 819

    Session Title: Hepatitis B: Therapeutics: New Agents

    Presenter: Kusum Gupta

    Summary: Aligos' ASO therapeutic candidate ALG-020572 was shown to potently inhibit HBsAg in vitro and in vivo. The antiviral activity, hepatocyte targeting and a favorable PK profile of ALG-020572 following SC administration warrants its advancement into clinical development as a potential treatment for CHB.

    siRNA

    Title: Incorporation of Novel siRNA Chemistries Significantly Improves the Potency and Durability of HBV siRNAs in the AAV-HBV Mouse Model

    Publication Number: 831

    Session Title: Hepatitis B: Therapeutics: New Agents

    Presenter: Jin Hong

    Summary: Aligos' nonclinical small interfering RNA (siRNA) therapeutic candidates in development for CHB demonstrated improved potency and/or durability in vitro and in vivo when modified with novel siRNA chemistries.

    Combinations

    Title: Triple Combination of Anti-Hepatitis B Virus Drugs Demonstrates Synergistic Activity In Vitro

    Publication Number: 852

    Session Title: Hepatitis B: Therapeutics: New Agents

    Presenter: Hua Tan

    Summary: Aligos' siRNA compound in development against hepatitis B virus, ALG-125755, in combination with the company's ASO, ALG-020572, and STOPS™ molecule, ALG-010133, demonstrated synergistic activity in cell culture with respect to reducing HBsAg when added to various triple-combination groupings with nucleos(t)ide analogs (NA), CAM or interferon.

    Triple combinations of the siRNA ALG-125755 and STOPS ALG-010133 with the ASO ALG-020572 showed additive activity in reducing HBsAg and demonstrated a dose-dependent response with respect to the ASO. When interferon or STOPS were added to the ASO-siRNA combination, the effect was enhanced, indicating the possibility of lowering doses needed to treat HBV when combined with other HBV therapies. Additionally, when tested in pairwise combinations with a NA or CAM, the compounds demonstrated additive to synergistic interactions on inhibition of HBV DNA.

    NASH



    Title: Preclinical Pharmacokinetic Profiling of ALG-055009, a Potent and Selective Thyroid Hormone Receptor Beta Agonist for the Treatment of Nonalcoholic Steatohepatitis, and Prediction of its Human Pharmacokinetics

    Publication Number: 1932

    Session Title: NAFLD and NASH: Therapeutics

    Presenter: Kusum Gupta

    Summary: The nonclinical pharmacokinetic properties of ALG-055009 in several animal model species indicate efficacious doses in the clinic are likely to be once daily doses in the sub- to low milligram range and there is likely a with low risk of drug-drug interactions.

    Title: Development of a Novel Seven-Day Dosing Mouse Efficacy Model to Evaluate Thyroid Hormone Receptor Agonists for the Treatment of NASH

    Publication Number: 1907

    Session Title: NAFLD and NASH: Therapeutics

    Presenter: Xuan Luong

    Summary: Authors developed a high-cholesterol diet (HCD) mouse model for efficient in vivo screening of THR-β agonists as potential therapeutic agents in nonalcoholic steatohepatitis (NASH). The model appears to be predictive of patient response at clinically relevant exposures and provides a rapid alternative to the time-consuming standard efficacy models developed through high-fat diet administration.

    About Aligos

    Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos's strategy is to harness the deep expertise and decades of drug development experience its team has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules.

    Forward-Looking Statement

    This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered "forward-looking statements," including, without limitation, statements regarding our belief that that combining multiple modalities that reduce hepatitis B virus S-antigen together with drugs that inhibit viral replication will be the key to achieving enhanced functional cure rates in people living with CHB and that the preclinical pharmacokinetic profile of our THR-β agonist drug candidate, ALG-055009, will support once-daily dosing in humans and have a low risk of drug-drug interactions. Forward-looking statements are typically, but not always, identified by the use of words such as "may," "will," "would," "believe," "intend," "plan," "anticipate," "estimate," "expect," and other similar terminology indicating future results. Such forward-looking statements are subject to substantial risks and uncertainties that could cause our development programs, future results, performance or achievements to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include without limitation risks and uncertainties inherent in the drug development process, including Aligos's clinical-stage of development, the process of designing and conducting clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, Aligos's ability to successfully establish, protect and defend its intellectual property, other matters that could affect the sufficiency of Aligos's capital resources to fund operations, reliance on third parties for manufacturing and development efforts, changes in the competitive landscape and the effects on our business of the worldwide COVID-19 pandemic. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 4, 2021, and its future periodic reports to be filed with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.

    Media Contact

    Amy Jobe, Ph.D.

    LifeSci Communications

    +1 315 879 8192

     

    Investor Contact

    Corey Davis, Ph.D.

    LifeSci Advisors

    +1 212 915 2577

     



    Primary Logo

    View Full Article Hide Full Article
View All Aligos Therapeutics Inc. News